TFAM and Parkinson disease: Although the MitoPark mouse has been found to be the most useful transgenic model in evaluating PD progression as well as response to therapies such as L-DOPA [232], the model’s translatability is still questionable, considering that alterations in TFAM have not been confirmed in human PD pathophysiology.